GRAIL Appoints Sarah Krevans to Board of Directors
GRAIL, Inc. (Nasdaq: GRAL) has announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Krevans will serve on the Board's Audit, Compensation, and Nominating and Governance Committees. With her addition, the Board now consists of five directors, four of whom are independent.
Krevans served as president and CEO of Sutter Health from 2016 to 2022, overseeing an integrated network of 14,000 clinicians, 24 hospitals, and various healthcare services. Her leadership focused on advancing clinical programs, innovation, and digital health to improve patient accessibility.
Bob Ragusa, CEO of GRAIL, expressed confidence in Krevans' ability to bring valuable experience to GRAIL's mission of establishing a new standard for multi-cancer early detection. Krevans' extensive healthcare background includes executive roles at Kaiser Permanente and in Maine's healthcare administration. She holds master's degrees in business administration and public health from UC Berkeley and has been recognized as one of the top healthcare leaders by Modern Healthcare.
GRAIL, Inc. (Nasdaq: GRAL) ha annunciato la nomina di Sarah Krevans nel suo Consiglio di Amministrazione, con effetto immediato. Krevans farà parte delle Commissioni di Audit, Compensi e Nomina e Governance del Consiglio. Con il suo ingresso, il Consiglio ora è composto da cinque membri, quattro dei quali sono indipendenti.
Krevans è stata presidente e CEO di Sutter Health dal 2016 al 2022, supervisionando una rete integrata di 14.000 medici, 24 ospedali e vari servizi sanitari. La sua leadership si è concentrata sull'avanzamento dei programmi clinici, sull'innovazione e sulla salute digitale per migliorare l'accessibilità ai pazienti.
Bob Ragusa, CEO di GRAIL, ha espresso fiducia nella capacità di Krevans di portare un'esperienza preziosa alla missione di GRAIL di stabilire un nuovo standard per la rilevazione precoce dei tumori multipli. Il vasto background di Krevans nel settore sanitario include ruoli dirigenziali presso Kaiser Permanente e nell'amministrazione sanitaria del Maine. Possiede una laurea magistrale in amministrazione aziendale e salute pubblica presso UC Berkeley ed è stata riconosciuta come una delle principali leader nel settore sanitario da Modern Healthcare.
GRAIL, Inc. (Nasdaq: GRAL) ha anunciado el nombramiento de Sarah Krevans en su Junta Directiva, con efecto inmediato. Krevans formará parte de las Comisiones de Auditoría, Compensación y Nominación y Gobernanza de la Junta. Con su incorporación, la Junta ahora consta de cinco miembros, de los cuales cuatro son independientes.
Krevans fue presidenta y CEO de Sutter Health desde 2016 hasta 2022, supervisando una red integrada de 14.000 clínicos, 24 hospitales y varios servicios de salud. Su liderazgo se centró en avanzar en programas clínicos, innovación y salud digital para mejorar la accesibilidad de los pacientes.
Bob Ragusa, CEO de GRAIL, expresó confianza en la capacidad de Krevans para aportar una valiosa experiencia a la misión de GRAIL de establecer un nuevo estándar para la detección temprana de múltiples tipos de cáncer. El amplio trasfondo de Krevans en el sector salud incluye roles ejecutivos en Kaiser Permanente y en la administración de salud de Maine. Posee maestrías en administración de empresas y salud pública de UC Berkeley y ha sido reconocida como una de las principales líderes en salud por Modern Healthcare.
GRAIL, Inc. (Nasdaq: GRAL)은 Sarah Krevans을 이사회의 이사로 즉시 임명한다고 발표했습니다. Krevans는 이사회의 감사, 보상 및 추천 및 거버넌스 위원회에서 활동하게 됩니다. 그녀의 합류로 이사회는 이제 다섯 명의 이사로 구성되며, 그 중 네 명은 독립적인 이사입니다.
Krevans는 2016년부터 2022년까지 Sutter Health의 회장 및 CEO로 재직하며 14,000명의 임상의, 24개의 병원 및 다양한 의료 서비스를 통합한 네트워크를 감독했습니다. 그녀의 리더십은 환자의 접근성을 개선하기 위한 임상 프로그램, 혁신 및 디지털 건강 발전에 중점을 두었습니다.
GRAIL의 CEO인 Bob Ragusa는 Krevans가 GRAIL의 다중 암 조기 발견이라는 사명을 위한 귀중한 경험을 가져올 수 있을 것이라고 확신했습니다. Krevans의 방대한 의료 배경은 Kaiser Permanente와 메인주의 의료 행정에서의 경영진 역할을 포함합니다. 그녀는 UC Berkeley에서 경영학 및 공공 보건 석사 학위를 보유하고 있으며, Modern Healthcare에 의해 의료 분야의 주요 리더 중 하나로 인정받았습니다.
GRAIL, Inc. (Nasdaq: GRAL) a annoncé la nomination de Sarah Krevans au sein de son Conseil d'Administration, avec effet immédiat. Krevans siègera aux comités d'Audit, de Rémunération et de Nomination et de Gouvernance du Conseil. Avec son ajout, le Conseil compte désormais cinq administrateurs, dont quatre sont indépendants.
Krevans a été présidente et PDG de Sutter Health de 2016 à 2022, supervisant un réseau intégré de 14 000 cliniciens, 24 hôpitaux et divers services de santé. Son leadership s'est concentré sur l'avancement des programmes cliniques, de l'innovation et de la santé numérique pour améliorer l'accessibilité des patients.
Bob Ragusa, PDG de GRAIL, a exprimé sa confiance en la capacité de Krevans à apporter une expérience précieuse à la mission de GRAIL visant à établir une nouvelle norme pour la détection précoce des cancers multiples. L'expérience étendue de Krevans dans le secteur de la santé comprend des postes exécutifs chez Kaiser Permanente et dans l'administration de la santé du Maine. Elle détient des diplômes de maîtrise en administration des affaires et en santé publique de l'UC Berkeley et a été reconnue comme l'une des meilleures leaders du secteur de la santé par Modern Healthcare.
GRAIL, Inc. (Nasdaq: GRAL) hat die Ernennung von Sarah Krevans in den Vorstand mit sofortiger Wirkung bekannt gegeben. Krevans wird Mitglied der Prüfungsausschüsse, Vergütung und Nominierung und Governance des Vorstands. Mit ihrem Eintritt besteht der Vorstand jetzt aus fünf Direktoren, von denen vier unabhängig sind.
Krevans war von 2016 bis 2022 Präsidentin und CEO von Sutter Health und verantwortete ein integriertes Netzwerk von 14.000 Klinikern, 24 Krankenhäusern und verschiedenen Gesundheitsdiensten. Ihre Führung konzentrierte sich darauf, klinische Programme, Innovation und digitale Gesundheit voranzutreiben, um die Zugänglichkeit für Patienten zu verbessern.
Bob Ragusa, CEO von GRAIL, äußerte Vertrauen in Krevans' Fähigkeit, wertvolle Erfahrungen in die Mission von GRAIL einzubringen, einen neuen Standard für die Früherkennung von mehreren Krebserkrankungen zu setzen. Krevans umfangreicher Hintergrund im Gesundheitswesen umfasst Führungspositionen bei Kaiser Permanente und in der Gesundheitsverwaltung von Maine. Sie hat Masterabschlüsse in Betriebswirtschaftslehre und öffentlicher Gesundheit von der UC Berkeley und wurde von Modern Healthcare als eine der führenden Führungskräfte im Gesundheitswesen ausgezeichnet.
- Appointment of Sarah Krevans, an experienced healthcare leader, to the Board of Directors
- Increased board independence with 4 out of 5 directors now independent
- Krevans' expertise in advancing clinical programs, innovation, and digital health aligns with GRAIL's mission
- Potential for valuable insights from Krevans' experience in leading a large, integrated healthcare network
- None.
Ms. Krevans served as president and CEO of Sutter Health, a
"Sarah is a highly accomplished healthcare leader with extensive experience in a dynamic and diverse environment," said Bob Ragusa, CEO of GRAIL. "I am confident that her experience will bring immense value to GRAIL as we move toward establishing a new standard of care for multi-cancer early detection for patients."
Previously, Ms. Krevans served as chief operating officer, and regional executive officer and president of the Sutter Health Sacramento Sierra Region. She also held executive roles at Kaiser Permanente and served as deputy director of
Ms. Krevans earned master's degrees in business administration and in public health from the University of
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-appoints-sarah-krevans-to-board-of-directors-302282199.html
SOURCE GRAIL, Inc.
FAQ
Who is Sarah Krevans and why was she appointed to GRAIL's Board of Directors?
What committees will Sarah Krevans serve on GRAIL's Board?
How does Sarah Krevans' appointment affect the composition of GRAIL's Board of Directors?